Kiniksa Pharmaceuticals L...

NASDAQ: KNSA · Real-Time Price · USD
33.81
0.53 (1.59%)
At close: Aug 15, 2025, 12:41 PM

Kiniksa Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
423.24M 270.26M 220.18M 38.54M
Cost of Revenue
60.91M 56.52M 46.97M 9.1M
Gross Profit
362.33M 213.74M 173.21M 29.44M
Operating Income
-45.62M -25.2M 7.37M -156.64M
Interest Income
n/a 8.54M 1.25M 97K
Pretax Income
-36.15M -16.65M 11.03M -156.54M
Net Income
-43.19M 14.08M 183.36M -157.92M
Selling & General & Admin
168.01M 129.43M 97.95M 85.95M
Research & Development
111.62M 76.1M 65.49M 99.3M
Other Expenses
128.31M 33.41M 1.25M 835K
Operating Expenses
407.94M 238.93M 163.44M 186.08M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
468.86M 295.45M 210.41M 195.18M
Income Tax Expense
7.04M -30.74M -172.34M 1.39M
Shares Outstanding (Basic)
71.42M 70.06M 69.38M 68.58M
Shares Outstanding (Diluted)
71.42M 71.92M 70.42M 68.58M
EPS (Basic)
-0.6 0.20 2.64 -2.3
EPS (Diluted)
-0.6 0.20 2.60 -2.3
EBITDA
-45.62M -22.86M 9.77M -154.28M
EBIT
-45.62M -25.2M 11.03M -156.64M
Depreciation & Amortization
n/a 2.34M 4.22M 4.09M